// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Associations between clinical factors and clinical course in peanut oral immunotherapy

Powell EA - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Paediatric food allergy: An educational video for medical students

Irwin KA - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastric antral vascular ectasia

N/A

Roxadustat for the Treatment of Anemia in CKD Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study

Barratt Jonathan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hypertension

roxadustat

Regional Variation of Erythropoietin-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)

Singh AjayK - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Erythropoietin

Calcium Isotopes: A Novel Biomarker of Bone Mineralization in CKD

Shroff Rukshana - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis

Chertow GlennMatthew - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Complex calcified coronary artery lesions

Ergocalciferol

Endotrophin, Released During Collagen Type VI Formation, Predicts Long-Term Mortality After AKI

Sparding Nadja - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Estimated Glomerular Filtration Rate Equations: Do We Need to Use the Ethnicity Correction Factor in People of African Ancestry Outside of the United States?

Gama Rouvick - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF

Kristensen S�ren�Lund - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart failure with reduced ejection fraction

Dapagliflozin

Efficacy and Safety of Difelikefalin for Moderate-to-Severe CKD–Associated Pruritus: A Global Phase 3 Study in Hemodialysis Patients (KALM-2)

Wooldridge ThomasD - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Uraemic pruritus

Difelikefalin

Nefecon® (Budesonide) Selectively Reduces Circulating Levels of BAFF (BLyS) and Soluble BCMA and TACI in IgA Nephropathy

Molyneux Karen - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

IgA nephropathy

Budesonide

Epigenome-Wide Microarray Analysis of Pre- and Post-Transplant Methylation Profiles in Kidney Transplant Recipients

Kerr Katie - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effects of Dapagliflozin on Kidney Function, Cardiovascular Events, and All-Cause Mortality According to Cause of Kidney Disease in the DAPA-CKD Trial

Wheeler DavidC - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

Dapagliflozin

Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6

Tuttle KatherineR - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Semaglutide

Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes

Agarwal Rajiv - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

Spironolactone

Activation of AMP-Activated Protein Kinase In Vivo Leads to a Polycystic Kidney Disease

Wilson Laura - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Polycystic kidney disease

N/A

Small Molecule Inhibitor of TMEM16A Chloride Channel Blocks Vascular Smooth Muscle Contraction and Lowers Blood Pressure in Spontaneously Hypertensive Rats

Cil Onur - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with CKD, Diabetes, and Recent Acute Coronary Syndrome: Results from the BETonMACE Trial

Kalantar-Zadeh Kamyar - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Congestive heart failure

RVX-208

Variation in Peritoneal Dialysis-Related Peritonitis Outcomes and Treatment Practices: Results from the Peritoneal Dialysis Outcomes and Practice Patterns Study

Al sahlawi Muthana - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Peritonitis

N/A

Steady Concentration Peritoneal Dialysis Increases Ultrafiltration and Sodium Removal Compared with Continuous Ambulatory Peritoneal Dialysis (CAPD)

Heimburger Olof - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved